10-K: Elevation Oncology Reports 2024 Financial Results and Provides Business Update

Sentiment:

Annual Results 6 March 2025 9:17 PM

📋All filings for Elevation Oncology, INC

Elevation Oncology's 10-K filing summarizes the company's financial performance in 2024 and provides updates on its clinical development programs, including EO-3021 and EO-1022.

Capital raiseThe company will need to raise substantial additional capital from the sale of its securities, debt, partnering arrangements, non-dilutive fundraising or other financing transactions in order to continue to fund its operations and finance the remaining development and commercialization of EO-3021 and EO-1022.The company may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.

Worse than expectedThe company has incurred significant operating losses since its inception in 2019 and has not generated any revenue.The company's current resources are insufficient to fund its planned operations for the next 12 months.

Summary

Elevation Oncology is focused on developing selective cancer therapies, with lead candidate EO-3021 targeting Claudin 18.2 and EO-1022 targeting HER3.
EO-3021 is in a Phase 1 clinical trial, with initial data showing a 42.8% objective response rate in a biomarker-enriched population.
The company is focusing EO-3021's development on firstand second-line treatment of advanced gastric/GEJ cancer.
Preclinical data suggests EO-3021 has combination potential with VEGFR2 or PD-1 inhibitors.
EO-1022 is a HER3 ADC, with preclinical data expected in the second quarter of 2025 and an IND application planned for 2026.
The company had a net loss of $44.5 million in 2024 and $45.7 million in 2023.
As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $93.2 million, expected to fund operations into 2026.
The company relies on third-party manufacturers, including CSPC for EO-3021, and is subject to competition from other companies developing similar therapies.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. Positive clinical data and future plans are offset by financial losses and the need for additional funding. The company is making progress but faces significant challenges.

Positives

EO-3021 demonstrated a competitive efficacy and a differentiated safety profile, including minimal hematological toxicity and hepatotoxicity, and no peripheral neuropathy/hypoesthesia.
EO-3021 was granted Fast Track designation by the FDA for the treatment of patients with advanced or metastatic gastric/GEJ cancer expressing Claudin 18.2 that has progressed on or after prior therapy.
The company has an active Investigational New Drug (IND) application for EO-3021 with the U.S. Food and Drug Administration (the FDA).
The company has global access to Syanffixs clinical stage, site-specific ADC technology platform, which we are using to develop EO-1022.

Negatives

The company has incurred significant operating losses since its inception in 2019 and has not generated any revenue.
The company's current resources are insufficient to fund its planned operations for the next 12 months.
The company is dependent on third-party manufacturers, including CSPC in China, which increases the risk of supply disruptions.
The company faces substantial competition from other companies developing cancer therapies, including those targeting Claudin 18.2 and HER3.

Risks

The company's ability to continue as a going concern is subject to material uncertainty and dependent on its success at raising additional capital.
The company is highly dependent on the success of its lead product candidate, EO-3021, and may never obtain approval for it or any other product candidate.
Delays in enrolling patients in clinical trials could delay or prevent regulatory approval.
Adverse side effects associated with product candidates could delay or preclude approval or limit their commercial potential.
The company faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than it does.
If the company or its licensors are unable to obtain and maintain sufficient patent protection for its product candidates, third parties could develop and commercialize similar products.

Future Outlook

The company expects to continue to incur significant expenses and increasing operating losses for at least the next several years as it continues its clinical development of, seeks regulatory approval for, and commercializes its lead product candidate EO-3021 and its second product candidate EO-1022, and potentially adds personnel necessary to operate as a commercial-stage public company.

Industry Context

The document highlights the competitive landscape in the oncology and ADC space, with numerous companies pursuing similar targets like Claudin 18.2 and HER3. This underscores the need for Elevation Oncology to differentiate its product candidates and execute its clinical development plan effectively.

Comparison to Industry Standards

The document mentions Astellas Pharma's regulatory approval for a mAb targeting Claudin 18.2, setting a benchmark for Claudin 18.2-targeted therapies.
Merus has received regulatory approval for a bispecific antibody (zenocutuzumab) targeting HER2 and HER3.
The document references other companies developing ADCs targeting Claudin 18.2, including Antengene, AstraZeneca, Chia Tai Tianqing Pharmaceutical, Evopoint Biosciences, Innovent Biologics, LaNova Medicines, Merck KGaA/Jiangsu Hengrui, RemeGen, Shanghai Junshi Bioscience, Sichuan Kelun-Biotech Biopharmaceutical, SystImmune and TORL Biotherapeutics.
The document references other companies developing ADCs targeting HER3, including Alphamab Oncology, Daiichi Sankyo/Merck, Duality Biologics, Innovent Biologics, Jiangsu Hengrui, MediLink Therapeutics (Suzhou)/BioNTech, Multitude Therapeutics, Shanghai Institute of Biological Products and SystImmune/Bristol Myers Squibb.

Stakeholder Impact

Shareholders face the risk of dilution from future equity offerings.
Employees' job security is linked to the company's ability to secure funding and advance its pipeline.
Patients stand to benefit from successful development and approval of new cancer therapies.
Suppliers and creditors are subject to the company's financial stability and ability to meet its obligations.

Next Steps

Report additional monotherapy safety and efficacy data from the dose escalation and expansion portions of the EO-3021 clinical trial in the second quarter of 2025.
Present preclinical data for EO-1022 in the second quarter of 2025.
Report initial data from the combination cohorts of the EO-3021 clinical trial in the fourth quarter of 2025 or the first quarter of 2026.
Submit an IND application for EO-1022 in 2026.

Key Dates

Date	Description
2019-04-29	Elevation Oncology, Inc. was incorporated.
2019-05-01	Date of Dyax Agreement.
2019-05-01	Date of Selexis Agreement.
2019-05-01	Date of NIH Agreement.
2019-05-01	Date of Asset Purchase Agreement Relating to Seribantumab.
2020-11-01	EO-3021 was granted orphan drug designation by the FDA for the treatment of gastric cancer (including GEJ cancer).
2021-05-01	EO-3021 was granted orphan drug designation by the FDA for the treatment of pancreatic cancer.
2021-06-24	Effective date of 2021 Equity Incentive Plan.
2021-06-24	Effective date of 2021 Employee Stock Purchase Plan.
2022-07-01	Date of CSPC License Agreement.
2022-07-31	Date of CSPC License Agreement.
2022-07-31	Date of K2 HealthVentures LLC Term Loan.
2023-01-06	Date of Restructuring Employee Severance Benefits And Related Costs.
2023-06-08	Date of June Twenty Twenty Three Public Offering.
2023-06-13	Date of June Twenty Twenty Three Public Offering.
2024-01-01	Start of the year 2024.
2024-03-01	Date of Synaffix License Agreement.
2024-08-01	Elevation Oncology reported initial monotherapy data from the dose escalation portion of its ongoing Phase 1 clinical trial of EO-3021.
2024-09-01	EO-3021 was granted Fast Track designation by the FDA for the treatment of patients with advanced or metastatic gastric/GEJ cancer expressing Claudin 18.2 that has progressed on or after prior therapy.
2024-09-01	Elevation Oncology entered into a license agreement with Synaffix B.V. (Synaffix), giving us global access to Syanffixs clinical stage, site-specific ADC technology platform, which we are using to develop EO-1022.
2024-12-01	Elevation Oncology announced preclinical proof-of-concept data indicating the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors.
2024-12-31	End of the year 2024.
2025-02-28	As of February 28, 2025, there were 59,215,795 shares of the registrants common stock, par value $0.0001 per share, outstanding.
2025-03-06	Effective date of Insider Trading Policy.
2025-04-01	Elevation Oncology expects to report additional monotherapy safety and efficacy data from the dose escalation and expansion portions of the clinical trial in the second quarter of 2025.
2025-04-01	Elevation Oncology expects to present preclinical data for EO-1022 in the second quarter of 2025.
2025-10-01	Elevation Oncology expects to report initial data from the combination cohorts of the clinical trial in the fourth quarter of 2025 or the first quarter of 2026.
2026-01-01	Elevation Oncology expects to report initial data from the combination cohorts of the clinical trial in the fourth quarter of 2025 or the first quarter of 2026.
2026-01-01	Elevation Oncology expects to submit an IND application for EO-1022 in 2026.

Keywords

EO-3021, EO-1022, Claudin 18.2, HER3, ADC, clinical trial, oncology, cancer, biopharmaceutical, FDA

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.